nVerses Capital LLC Has $118,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

nVerses Capital LLC boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 52.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,500 shares of the biotechnology company’s stock after acquiring an additional 5,300 shares during the quarter. nVerses Capital LLC’s holdings in BioCryst Pharmaceuticals were worth $118,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BCRX. Xponance Inc. boosted its holdings in BioCryst Pharmaceuticals by 13.1% in the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 1,505 shares during the last quarter. Creative Planning boosted its holdings in BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after buying an additional 2,734 shares during the last quarter. CWM LLC boosted its holdings in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares during the last quarter. Diversified Trust Co boosted its holdings in BioCryst Pharmaceuticals by 18.0% during the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after buying an additional 3,774 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after buying an additional 4,041 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several recent analyst reports. Barclays lifted their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $14.17.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $7.62 on Monday. The business has a fifty day simple moving average of $7.81 and a 200 day simple moving average of $6.68. The company has a market capitalization of $1.57 billion, a PE ratio of -7.12 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million for the quarter, compared to the consensus estimate of $98.30 million. The business’s revenue was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.